Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02104661 (ClinicalTrials.gov)	October 2014	1/4/2014	Protective Role of Oxcarbazepine in Multiple Sclerosis	OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial	Multiple Sclerosis	Drug: Oxcarbazepine;Drug: Placebo	Queen Mary University of London	National Multiple Sclerosis Society;Novartis Pharmaceuticals;Barts & The London NHS Trust;University College, London;Royal Free Hospital NHS Foundation Trust;Southend University Hospital;Basildon and Thurrock University Hospitals NHS Foundation Trust;St George's Healthcare NHS Trust;Barnet and Chase Farm Hospitals NHS Trust	Completed	18 Years	60 Years	All	30	Phase 2	United Kingdom
2	EUCTR2013-002419-87-GB (EUCTR)	18/03/2014	07/02/2014	PROXIMUS (PRotective role of OXcabazepine In MUltiple Sclerosis)	Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial - PROXIMUS - PRotective role of OXcabazepine In MUltiple Sclerosis	Multiple sclerosis MedDRA version: 19.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Trileptal Product Name: Oxcarbazepine INN or Proposed INN: oxcarbazepine Other descriptive name: Trileptal	Queen Mary University London	NULL	Not Recruiting			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom